BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 19
• 20
• 21
• 22
• 23
• 26
• 27
• 28
• 29
• 30

• 

  Michael Pietrack

  Michael Pietrack is practice lead for Kaye/Bassman’s pharma and biotech recruiting team and host of “The Pharmaverse Podcast.” You can follow him on LinkedIn.  
• 

  Layoffs

  Layoff Dilemma: Would You Take Pay Cut, Demotion to Keep Your Job?

  To avoid being laid off, a third of biopharma professionals would take a pay cut and nearly a quarter would take a demotion, according to BioSpace LinkedIn polls. We spoke to several professionals about their layoff experiences and what they would—and wouldn’t—have done to keep their jobs.

  August 15, 2024

   · 

  6 min read

   · 

  Angela Gabriel
• 

  Drug Development

  Eyes Wide Open: Gaining Patient Trust in the Face of Evolving Women’s Health Policies in State Legislations

  Lori and guests address clinical trial design, which if done without careful consideration of the patient population can exclude patients from clinical trials instead of being inclusive.

  August 15, 2024

   · 

  1 min read

   · 

  Lori Ellis
• 

  Approvals

  Incyte Wins Second Graft-Versus-Host Disease FDA Approval

  Nearly two weeks ahead of its target action date, the regulator on Wednesday has signed off on Incyte and Syndax’s Niktimvo for the third-line treatment of graft-versus-host disease.

  August 15, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Approvals

  Gilead’s $4.3B Bet on CymaBay Pays Off With FDA Nod for Autoimmune Liver Disease Drug

  The regulator’s approval of Livdelzi for primary biliary cholangitis under the accelerated pathway is a boost to Gilead Sciences’ liver disease business. Analysts expect the drug to reach more than $1 billion in sales.

  August 15, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Policy

  IRA-Negotiated Drug Prices as Expected but Savings Not as Great as CMS Says

  The Biden administration on Thursday touted discounts of up to 79%, but many of these first 10 drugs are already sold well below list price.

  August 15, 2024

   · 

  5 min read

   · 

  Greg Slabodkin
• 

  IRA

  White House Expects IRA’s Negotiated Drug Prices to Save Medicare $6B in 2026

  The Biden administration on Thursday announced that the Inflation Reduction Act’s Medicare Drug Price Negotiation Program will save the U.S. government around $6 billion in its first year of implementation.

  August 15, 2024

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Layoffs

  Evotec Latest in String of August Biopharma Layoff Announcements

  Workforce reductions for the first half of August outpace May, June and July’s monthly totals.

  August 15, 2024

   · 

  2 min read

   · 

  Angela Gabriel
• 

  Gene therapy

  Bluebird Hit With Slow Uptake of Sickle Cell, Beta-Thalassemia Gene Therapies

  Likely to miss its initiation target, bluebird bio has renegotiated the loan deals of its agreement with Hercules Capital, giving it until June 30 next year—at the latest.

  August 15, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Brain-CA Technologies Secures Patents for Innovative AI based on Cellular Automata

  August 15, 2024

   · 

  3 min read